-
Insights by Ira: Mission Complete
Just four days prior to my inaugural public engagement as National Ambassador in 2024, I
-
Dyne, citing positive trial data, to ask FDA to approve DMD therapy
Dyne Therapeutics said it plans to ask the U.S. Food and Drug Administration (FDA) to
-
My hope for the FSHD community this Advent season
Advent is the beginning of the church year for Christians. What better way to start
-
Dyne announces positive topline results from Phase 1/2 trial of z-rostudirsen in Duchenne amenable to skipping exon 51
As an early investor in Dyne Therapeutics, we are pleased to share their exciting news
-
New trial results highlight gains in arm and heart function for DMD
In the Phase 3 HOPE-3 clinical trial, the experimental cell therapy deramiocel outperformed a placebo
-
Satellos receives clearance by FDA to initiate Phase 2 study in Duchenne
Satellos Biosciences has received Investigational New Drug (IND) clearance from the FDA, as well as
-
In Case You Missed It…
Quest Media is an innovative, adaptive lifestyle platform from MDA. With the power of this
-
Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne
Dyne Therapeutics has announced positive topline results from its Registrational Expansion Cohort (REC) of the
-
Finding the right words to describe our life experiences
Words matter. For that reason, I’d like to share my thoughts on language, chronic illness,
-
Clinical Research Alert: Phase 1b Study of SRD-001 in Adults with DMD-Related Cardiomyopathy
Researchers at Sardocor Corp are seeking adults with cardiomyopathy (heart disease) secondary to Duchenne muscular dystrophy
